公开(公告)号：US20200291094A1

公开(公告)日：2020-09-17

申请号：US16860613

申请日：2020-04-28

申请人： Janssen Biotech, Inc.

发明人： Steven JACOBS ,  Karyn O'NEIL

IPC分类号： C07K14/78

摘要： A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

公开(公告)号：US20230143550A1

公开(公告)日：2023-05-11

申请号：US17689869

申请日：2022-03-08

申请人： JANSSEN BIOTECH, INC.

发明人： Rebecca HAWKINS ,  Steven JACOBS ,  Manuel SEPULVEDA

IPC分类号： C07K14/78 ,  G01N33/569 ,  G01N33/68 ,  G01N33/566 ,  A61K51/08 ,  G01N33/53 ,  A61K49/00 ,  G01N33/574

CPC分类号： C07K14/78 ,  G01N33/56966 ,  G01N33/6887 ,  G01N33/566 ,  A61K51/088 ,  G01N33/53 ,  A61K49/0002 ,  G01N33/68 ,  G01N33/569 ,  G01N33/57492 ,  G01N33/574 ,  G01N2333/70517 ,  G01N2333/78

摘要： Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

公开(公告)号：US20190263915A1

公开(公告)日：2019-08-29

申请号：US16227597

申请日：2018-12-20

申请人： Janssen Biotech, Inc.

发明人： Shalom GOLDBERG ,  Steven JACOBS ,  Tricia LIN ,  Karyn O'Neil

IPC分类号： C07K16/28 ,  G01N33/74 ,  C07K14/78

摘要： Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.